Celltrion Launches U.S. Phase 4 Trial of 240mg High-Dose Zymfentra in Crohn's and Ulcerative Colitis
核心洞察
Celltrion has submitted an IND application to the FDA for a U.S. Phase 4 trial of a 240mg high-dose regimen of its subcutaneous infliximab, Zymfentra (搜索).
The trial will enroll 447 patients with Crohn's disease (搜索) and ulcerative colitis (搜索) across 55 U.S. sites, testing non-inferiority against high-dose intravenous infliximab.
Success would add a 240mg option to the current 120mg U.S. prescribing practice, mirroring a high-dose strategy that helped Remsima SC reach roughly 32% EU5 market share.
Celltrion has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for a Phase 4 clinical trial designed to establish evidence for a 240mg high-dose regimen of Zymfentra (搜索) (infliximab), the company's subcutaneous autoimmune disease therapy. The company announced the filing on the 15th, positioning the study as a step toward a tailored prescribing framework built around disease severity and individual patient condition.
The trial will enroll a total of 447 patients with Crohn's disease (搜索) (CD) and ulcerative colitis (搜索) (UC) across 55 U.S. sites. Its core objective is to demonstrate non-inferiority by comparing a high-dose intravenous (IV) infliximab arm against a 240mg Zymfentra (搜索) arm. Completion of the study would give Celltrion objective clinical data supporting 240mg dosing, which the company intends to use to add a high-dose option to current U.S. prescribing practice, presently centered on 120mg.
Extending a European Dosing Model to the U.S.
The strategy represents a U.S. expansion of a model Celltrion has already applied in Europe, where the product is marketed as Remsima SC. According to the company, Remsima SC reached approximately 32% market share in the EU5 (the top five European markets) as of the first quarter of this year, and Celltrion believes high-dose prescribing based on disease severity has materially contributed to that market expansion. After securing high-dose clinical data in the United States, the company plans to pursue a prescribing strategy combining both 120mg and 240mg doses.
Adding a high-dose option carries significance beyond convenience, establishing a basis for enhancing therapeutic efficacy. For inflammatory bowel disease (搜索) (IBD) patients who do not achieve an adequate response with standard dosing, high-dose administration can serve as an alternative. Celltrion expects that demonstrating the safety and efficacy of 240mg dosing will give physicians a broader range of treatment options.
Rheumatoid Arthritis Indication in Parallel Development
Alongside dose expansion, Celltrion is running global trials to broaden Zymfentra (搜索)'s U.S. prescribing scope beyond IBD to include rheumatoid arthritis (搜索) (RA). If the RA indication is added, the potential U.S. patient population eligible for Zymfentra is expected to expand significantly. The number of rheumatoid arthritis patients in the U.S. far exceeds the combined total of Crohn's disease (搜索) and ulcerative colitis (搜索) patients, and given that infliximab is widely used for RA treatment, adding the indication could expand Zymfentra's potential market several-fold compared with current levels.
The specific completion timeline for the global RA indication trials has not been disclosed. The high-dose Phase 4 trial is also expected to require considerable time for patient recruitment and data analysis. Celltrion's plan is to pursue both trials in parallel while progressively expanding its prescribing base in the U.S. market.
Commercial Traction and Competitive Positioning
Zymfentra (搜索)'s U.S. sales are showing steep growth, with first-half revenue this year reaching 99.5 billion won (approximately $73.6 million), up 176.4% year-over-year. Celltrion has secured insurance reimbursement coverage of over 90% through contracts with U.S. pharmacy benefit managers (PBMs) and distributes the product through its local subsidiary's direct sales network.
Zymfentra (搜索) is currently the only infliximab subcutaneous (SC) formulation sold in the United States. It has been marketed there for adult Crohn's disease (搜索) and ulcerative colitis (搜索) since receiving FDA approval in 2023. Unlike IV infliximab, which must be administered in a hospital setting, the SC formulation can be self-administered by patients at home, giving it a differentiated competitive edge in treatment convenience and quality of life.
The U.S. infliximab market is structured around competition between Johnson & Johnson's originator drug Remicade and multiple biosimilars. Celltrion entered with its IV biosimilar Remsima and subsequently launched Zymfentra (搜索), a subcutaneous formulation, through a novel drug approval pathway to achieve differentiation.
A Celltrion representative said, "This trial is intended to diversify tailored treatment options based on patient condition and enhance the clinical value of Zymfentra (搜索)," adding, "We will expand our presence in the U.S. autoimmune disease treatment market based on clinical data, product competitiveness, and direct sales capabilities."